November 08, 2016
RealTime Dynamix™: Psoriasis
RealTime Dynamix: Psoriasis Q2 is the baseline first report in a three-part 2016 series focusing on current and anticipated future trends in the PsO market. Report content includes current and future patient share, treatment satisfaction, industry contact rates, awareness and familiarity with products in development, sources of information about development compounds, statement agreements, line of therapy analysis, treatment discontinuations, brand barriers, impact of biosimilars, and a detailed look at dermatologists’ adoption of Taltz. Major in-line brands covered include Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, and Taltz. PsO pipe-line agents covered include brodalumab, guselkumab, tildrakizumab, tofacitinib, and the recently approved biosimilar, Inflectra.